- Trial phase
- Phase 1 completed; advancing to Phase 2
- Time to market
- XEN1701 has just completed Phase 1 and is advancing to Phase 2 proof-of-concept studies. Assuming successful Phase 2 and Phase 3 trials, potential approval would be several years away, likely in the 2030s at the earliest.
- Why 2/10
- XEN1701 has no hard dated binary catalyst in the next ~12 months. It recently completed Phase 1 (positive data announced October 29, 2026) and management plans to advance it to Phase 2 proof-of-concept studies in acute pain, but no specific start date or readout timeline has been given. XEN1701 is an early-stage pipeline asset at a company whose value is dominated by its lead drug azetukalner (NDA submitted for focal seizures, Phase 3 depression readout due December 2026). ImpactScore is low at 2.
XEN1701 is an early-stage (Phase 1 completed) non-opioid pain candidate at Xenon, which is far from a binary catalyst. The next event to watch is initiation of Phase 2 proof-of-concept studies in acute pain, which management indicated is planned but has not given a specific date. The much larger near-term catalyst for XENE stock is the Phase 3 X-NOVA2 depression data for lead asset azetukalner expected in December 2026, and the FDA review of the azetukalner NDA for focal seizures (submitted September 2026). XEN1701 itself is unlikely to drive material share price movement in the next 12 months.
Price Chart
Executive Summary
XEN1701 is an investigational Nav1.7 sodium channel inhibitor being developed by Xenon Pharmaceuticals (XENE, Nasdaq) as a non-opioid treatment for acute pain. On October 29, 2026, Xenon announced positive Phase 1 results at the IASP 2026 conference, showing XEN1701 achieved its target receptor occupancy profile with good tolerability and no notable cardiovascular effects. The company is advancing XEN1701 (along with a second pain candidate, XEN1120) to Phase 2 proof-of-concept studies in acute pain. XEN1701 is an early-stage pipeline asset at Xenon; the company's primary value driver is its lead drug azetukalner (XEN1101), which has an NDA submitted to the FDA for focal seizures and a Phase 3 depression readout (X-NOVA2) expected in December 2026.
How It Works
XEN1701 is a Nav1.7 sodium channel inhibitor. Sodium channels on nerve cells act like gates that open to let sodium ions in, triggering pain signals to the brain. By blocking the Nav1.7 channel specifically, XEN1701 aims to stop pain signals at their source in the peripheral and central nervous system, without the addictive properties of opioid drugs. It is a non-opioid, non-addictive approach to treating acute pain.
Trial Status
XEN1701 completed Phase 1 with positive results announced on October 29, 2026 at the IASP 2026 conference. The Phase 1 study demonstrated desired Nav1.7 receptor occupancy in both peripheral and central nervous systems, and the drug was generally well-tolerated with no notable autonomic cardiovascular effects. Management stated in the Q3 2026 earnings update (November 9, 2026) that XEN1701 is advancing toward Phase 2 proof-of-concept studies in acute pain, though no specific start date has been announced.
The Two-Sided Case
Upcoming Catalysts
- Initiation of Phase 2 proof-of-concept studies in acute pain (timing not yet specified)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Xenon Pharmaceuticals Inc. 8-K XENE ·Originating report